{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-270330","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2026-06-15T12:16:14+00:00","discovered_at":"2026-06-15T12:20:00.342208+00:00","generated_at":"2026-06-15T12:20:11.738132+00:00","sec_items":["1.02","5.02","5.03","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Faeth Therapeutics (fka Sensei) appoints new CEO, CFO; PIKTOR Phase 2 data expected H2 2026","bullets":["Name changed to Faeth Therapeutics; ticker to FTH effective June 16, 2026; Austin HQ.","Anand Parikh appointed Chairman, President & CEO; Brian Stephenson appointed CFO.","Board adds former FDA Commissioner Stephen M. Hahn and Saira Ramasastry.","Series B preferred stock converted; $200M gross proceeds from Feb 2026 private placement.","PIKTOR (oral PI3K/AKT/mTOR inhibitor) Phase 2 topline data in advanced endometrial cancer expected H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-270330","json":"https://secwatch.observer/filing/0001193125-26-270330.json","markdown":"https://secwatch.observer/filing/0001193125-26-270330.md","text":"https://secwatch.observer/filing/0001193125-26-270330.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/0001193125-26-270330-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/d144622d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T12:20:11.738132+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"077dbc037e","claim":"Anand Parikh was appointed as President and Chief Executive Officer at Sensei Biotherapeutics, Inc..","evidence_excerpt":"The Board of Directors (the “Board”) of the Company appointed Anand Parikh as President and Chief Executive Officer of the Company, effective as of June 13, 2026","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/0001193125-26-270330-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"537e9fe101","claim":"Brian Stephenson was appointed as Chief Financial Officer at Sensei Biotherapeutics, Inc..","evidence_excerpt":"Effective as of June 13, 2026, Brian Stephenson was appointed as the Company’s Chief Financial Officer and principal financial officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/0001193125-26-270330-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"64c2e6a374","claim":"Thomas Ricks resigned as Director at Sensei Biotherapeutics, Inc..","evidence_excerpt":"effective as of June 12, 2026, Christopher W. Gerry, Thomas Ricks and Kristian Humer resigned from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/0001193125-26-270330-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"689e147a42","claim":"Christopher W. Gerry resigned as Director at Sensei Biotherapeutics, Inc..","evidence_excerpt":"effective as of June 12, 2026, Christopher W. Gerry, Thomas Ricks and Kristian Humer resigned from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/0001193125-26-270330-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6ff222c419","claim":"Kristian Humer resigned as Director at Sensei Biotherapeutics, Inc..","evidence_excerpt":"effective as of June 12, 2026, Christopher W. Gerry, Thomas Ricks and Kristian Humer resigned from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/0001193125-26-270330-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8b6b014811","claim":"Josiah Craver was appointed as Senior Vice President of Finance and principal accounting officer at Sensei Biotherapeutics, Inc..","evidence_excerpt":"Effective as of June 13, 2026, Josiah Craver was ratified as the Company’s Senior Vice President of Finance and appointed as principal accounting officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/0001193125-26-270330-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President of Finance and principal accounting officer"}],"fact_type":"executive_change"},{"claim_id":"6cb7eef046f12024d3d6b85d2ff6c05d85c5b63b","claim":"Sensei Biotherapeutics, Inc.: Company filed an amendment to its Amended and Restated Certificate of Incorporation to change its name from Sensei Biotherapeutics, Inc. to Faeth Therapeutics, Inc (effective 2026-06-15).","evidence_excerpt":"On June 15, 2026, the Company filed with the Secretary of State of the State of Delaware an amendment to its Amended and Restated Certificate of Incorporation to change the name of the Company from \"Sensei Biotherapeutics, Inc.\" to \"Faeth Therapeutics, Inc.\" (the \"Name Change Amendment\"). The Name Change Amendment became effective immediately upon filing.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/0001193125-26-270330-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2026-06-15"}],"fact_type":"governance_change"},{"claim_id":"3d36cc5ea7bd418766baa388b514d3d679da7966","claim":"Sensei Biotherapeutics, Inc. terminated Sales Agreement with Jefferies LLC valued at $50,000,000 (effective 2026-06-10).","evidence_excerpt":"Item 1.02 Termination of a Material Definitive Agreement. As previously disclosed, on March 15, 2022, Faeth Therapeutics, Inc., formerly known as Sensei Biotherapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Prior Sales Agreement”) with Jefferies LLC (“Jefferies”), pursuant to which the Company from time to time may offer and sell shares of its common stock through or to the Agent having an aggregate offering price of up to $50 million. On June 10, 2026, the Company delivered written notice to Jefferies to terminate the Prior Sales Agreement, effective immediately, in accordance with the terms of the Prior Sales Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/0001193125-26-270330-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Jefferies LLC"},{"label":"Value","value":"$50,000,000"},{"label":"Effective","value":"2026-06-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}